Delivery Order SPE2DB20D1100-SPE2DB24FB8B1
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml to the Defense Logistics Agency (DLA). The contract has a ceiling value of $3,544.68 and is a firm fixed-price delivery order with an ultimate completion date of October 11, 2022. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The $1,706.87 Firm Fixed Price Delivery Order is for the supply of the pharmaceutical product Ozempic 2 mg/dose (8 mg/3 ml) 3 ml. The contract has an ultimate completion date of June 28, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical which serves...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml pharmaceutical product to the Defense Logistics Agency (DLA). The firm-fixed-price delivery order is valued at $2,322.16 and has an ultimate completion date of July 9, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical as the primary vehicle to...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a delivery order valued at $10,158.96 for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml medication. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of May 30, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to...
- This federal contract award to AmerisourceBergen Drug Corp's Corporate Office division is a delivery order valued at $4,644.32 for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml. The contract has an ultimate completion date of August 19, 2024 and was awarded on August 16, 2024 by the Defense Logistics Agency (DLA), a defense agency. This award is likely part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at up to...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,449.63, is a Firm Fixed Price delivery order for Ozempic 2 mg/dose (8 mg/3 ml) 3 ml. The award has a completion date of November 13, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $53,727.38 for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml pharmaceutical products. The contract has a Firm Fixed Price pricing type and an ultimate completion date of December 2, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC)...
- This federal contract award is to Amerisourcebergen Drug Corp's Corporate Office division, a major pharmaceutical distributor and supplier of medical commodities to the U.S. government. The $3,958.20 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA) Troop Support Medical for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, with a completion date of September 24, 2024. This award is under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 through...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml to the Defense Logistics Agency (DLA). The $19,276.93 firm fixed price delivery order contract has an ultimate completion date of October 30, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical that serves as a primary vehicle for providing a comprehensive range of...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a $8,212.23 firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) for the product Ozempic 2 mg/dose (8 mg/3 ml) 3 ml. The contract has an ultimate completion date of September 16, 2024 and was awarded on September 14, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB24FB8B1Delivery Order
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a delivery order valued at $1,741.62 for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml to the Defense Logistics Agency (DLA). The contract has a firm fixed price pricing type and an ultimate completion date of May 16, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024. This contract award does not have a set-aside designation and was made on a full and open competition basis, highlighting Amerisourcebergen's competitive position in the federal pharmaceutical supply market.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 5/15/24 |